Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022
SEATTLE and VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
News
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical…
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company…
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical…
Alimera Sciences Reports Fourth Quarter and FY 2021 Results
Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of…
Immutep to Present at Healthcare Investor Conferences
SYDNEY, AUSTRALIA, Feb. 24, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or…
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
— FDA sets updated PDUFA goal date of June 16, 2022 — — Company also…
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to…
Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
Full-Year 2021 Total Revenue Growth of 26% Full-Year 2022 Total Revenue Guidance of $178 to…
Science 37®’s Operating System Receives ISO Certification for Information Security Management
ISO 27001 certification and ISO 27701:2019 extension demonstrate Science 37’s commitment to quality, cybersecurity and…
Genenta to Participate at Upcoming Investor Conferences
MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
Chalice Brands Ltd. Pre-announces 61% Year Over Year Fourth Quarter Growth and Record Yearly Revenues
PORTLAND, Ore., Feb. 24, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF)…
Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference
WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA),…
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
On track to present additional interim data from dose-escalation portion of the ongoing Phase 1…
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021
Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis…
JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level
Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared…
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the…
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET NEW YORK,…
Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update
– FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV®sales – Second half fiscal…
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial…